Washington 2019-2020 Regular Session Status: Passed House 10 D cosponsors

HB 2428 — Studying students' life-threatening allergic reactions.

Last action — Referred to Appropriations.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2019-2020 Regular Session. It reached “Passed House” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there are no live odds of enactment. It would have to be reintroduced in the current session to move again.

Bill Text

What changed in the latest version

1 added · 1 removed

Plain-language change summary

The updated bill HB 2428 now establishes a work group focused on improving how schools handle life-threatening allergic reactions in students, instead of just requiring a report on existing practices. This work group will include a variety of stakeholders, such as school nurses, parents, and health professionals, who will analyze data and make specific recommendations to enhance prevention and treatment strategies. This change matters because having a diverse group working together can lead to better policies that not only address expenses related to epinephrine autoinjectors but also ensure the safety of students with allergies.

→
Previous
Latest
H-4396.2SUBSTITUTE HOUSE BILL 2428State of Washington66th Legislature2020 Regular SessionByHouse Education (originally sponsored by Representatives Duerr, Walen, Springer, Santos, Ramel, Shewmake, Doglio, Kilduff, Paul, and Pollet)READ FIRST TIME 02/05/20.AN ACT Relating to students' life-threatening allergic reactions;
H-3388.1HOUSE BILL 2428State of Washington66th Legislature2020 Regular SessionByRepresentatives Duerr, Walen, Springer, Santos, Ramel, Shewmake, Doglio, Kilduff, Paul, and PolletRead first time 01/14/20.Referred to Committee on Education.AN ACT Relating to students' life-threatening allergic reactions;
creating a new section;
adding a new section to chapter 28A.630 RCW;
(1)(a) By December 1, 2020, and in compliance with RCW 43.01.036, the office of the superintendent of public instruction and the department of health must collaborate to submit to the appropriate committees of the legislature a report of findings related to statewide implementation of RCW 28A.210.383, authorizing prescriptions for, and use of, school supplies of epinephrine autoinjectors.(b) In preparing the report, the office of the superintendent of public instruction and the department of health must:(i) Analyze information about the schools that maintain a supply of epinephrine autoinjectors under RCW 28A.210.383;(ii) Examine the barriers and challenges licensed health professionals with the authority to prescribe epinephrine autoinjectors experience in prescribing this medication under a standing order;(iii) Review whether and to what extent the requirement under RCW 28A.210.320 that a student with a life-threatening allergic reaction present a medication or treatment order addressing the medical services that may be required to be performed at the school reduces the need for and use of a school supply of epinephrine autoinjectors;(iv) Determine the number of unused epinephrine autoinjectors discarded by schools, and returned to students' families, at the end of the 2020-21 school year;(v) Complete an inventory of the number and categories of school district staff provided with training on identifying and responding to life-threatening allergies between September 1, 2017, and September 1, 2020;
A new section is added to chapter 28A.630 RCW to read as follows:(1)(a) The EpiPen work group is established to make recommendations on improving the prevention and treatment of students' life-threatening allergic reactions in schools serving kindergarten through twelfth grade students.
and(vi) Investigate any other implementation issues raised by school nurses, students who have life-threatening allergic reactions, and students' families during meetings held by the office of the superintendent of public instruction for the purpose of soliciting feedback on these issues.(2) When collecting and analyzing information as required under subsection (1) of this section, the office of the superintendent of public instruction and the department of health must collect information from multiple sources, and disaggregate information during analysis, such that information can be separated by school geography, student enrollment, school socioeconomic status, and other student demographics.(3) This section expires August 31, 2021.--- END ---
One goal of the work group is to recommend policies that will reduce the waste of epinephrine autoinjectors and the costs of purchasing this medication for schools and students' families.
Another goal of the work group is to analyze data collected by the office of the superintendent of public instruction in order to make data-informed decisions.(b) The office of the superintendent of public instruction must convene and staff the work group, and must consult the department of health and the health care authority as applicable.(2)(a) The work group must consist of the following members:(i) A school board director recommended by the Washington state school directors' association;(ii) A school superintendent recommended by a Washington association of school administrators;(iii) A school principal recommended by a Washington association of school principals;(iv) A school nurse who works full time at one or two schools recommended by a Washington association of school nurses;(v) A school nurse who is part of the school nurse corps program recommended by a Washington association of school nurses;(vi) A school employee who has agreed to the use of epinephrine autoinjectors as a specific part of their job description recommended by a Washington association of school employees;(vii) A representative of the nursing care quality assurance commission with expertise in standards of nursing practice and the principals of delegation in a school setting recommended by the commission;(viii) A parent of a student with a life-threatening allergy recommended by a nonprofit organization representing people with asthma and allergies for over fifty years;(ix) A student with a life-threatening allergy recommended by a Washington association of parents, teachers, and students;(x) A school health services expert selected by the superintendent of public instruction;(xi) A pediatric physician certified by the American board of allergy and immunology recommended by a Washington association of physicians;(xii) A pharmacist with experience dispensing epinephrine autoinjectors to schools under a standing order recommended by a Washington association of pharmacists;
and(xiii) An attorney with experience representing school districts recommended by a Washington association of school attorneys.(b) To the extent possible, the members of the work group must be racially and ethnically diverse and must represent urban, suburban, and rural locations across the state.(c) The work group must elect cochairs from the members described in this subsection (2), one from the education sector and the other from the health sector.(3) The office of the superintendent of public instruction must survey public schools to collect the following data for the 2020-21 school year:(a) For students with life-threatening allergic reactions, the number of medication orders, individual health care plans, and emergency care plans;
and whether a prescription for an epinephrine autoinjector is on file;(b) The approximate number of epinephrine autoinjectors maintained by schools disaggregated by source;(c) The number of epinephrine autoinjectors administered to and by students, disaggregated by:
(i) The source of the medication;
(ii) the category of person who administered the medication;
(iii) whether the student does or does not have a prescription for an epinephrine autoinjector on file;
and (iv) the location of medication administration;(d) The number and types of school personnel designated and trained to administer epinephrine autoinjectors as described in RCW 28A.210.383;
and(e) The number of letters of refusal to use epinephrine autoinjectors filed compared to the total number of school employees.(4) At a minimum, the work group must:(a) Analyze the survey data collected as required under subsection (3) of this section;(b) Review federal and state laws and state guidelines related to nursing care, children with life-threatening conditions, students with asthma and anaphylaxis, epinephrine autoinjectors in schools, and other relevant laws and guidelines;(c) Discuss topics for which recommendations are required under subsection (5) of this section.(5) By December 15, 2021, and in compliance with RCW 43.01.036, the office of the superintendent of public instruction must report to the appropriate committees of the legislature with a summary of the survey results, the work group's activities, and the work group's recommendations for state agencies and the legislature to improve the prevention and treatment of students' life-threatening allergic reactions in schools serving kindergarten through twelfth grade students.
If members of the work group do not agree with the content of the majority report, there may be a minority report included as an addendum to the majority report.
At a minimum, the work group must make recommendations on the following topics:(a) Required periodic data collection and analysis related to students' life-threatening allergic reactions, such as the data described in subsection (3) of this section;(b) Whether selling epinephrine autoinjectors singly would reduce epinephrine autoinjector waste without compromising student health and safety;(c) Whether the families of students with life-threatening allergic reactions should be required to provide epinephrine autoinjectors to a school that maintains a school stock of epinephrine autoinjectors and, if not, the minimum number of epinephrine autoinjectors per student that a school should maintain as school stock;(d) Whether to allow or require the administration of over-the-counter allergy medication to treat students' symptoms of allergic reactions, and under what circumstances;(e) Other ways to reduce the waste of epinephrine autoinjectors and the costs of purchasing this medication for schools and students' families, while maintaining students' safety and without increasing schools' liability;
and(f) Whether to allow designated trained school employees to administer epinephrine autoinjectors to students without prescriptions for epinephrine autoinjectors who are demonstrating the symptoms of anaphylaxis when a school nurse is not in the vicinity and, if so, policies and procedures to do this safely.(6) This section expires June 30, 2022.--- END ---
View plain text versions (2)

Action History

  1. Referred to Appropriations.

  2. Referred to Appropriations.

  3. Scheduled for public hearing in the House Committee on Education at 01:30 PM

  4. ED - Majority; 1st substitute bill be substituted, do pass.

  5. ED - Majority; 1st substitute bill be substituted, do pass.

  6. Scheduled for public hearing in the House Committee on Education at 01:30 PM

  7. First reading, referred to Education.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 9 co-sponsors · 141 not signed on

Sponsors (1)

Co-sponsors (9)

Not signed on (141)

141 members have not signed on to this bill.

Show all 141 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HB 2428?
HB 2428 is sponsored by Davina Duerr (Democrat), Amy Walen (Democrat), Larry Springer (Democrat), Sharon Tomiko Santos (Democrat), Alex Ramel (Democrat), Sharon Shewmake (Democrat), Beth Doglio (Democrat), Dave Paul (Democrat), Gerry Pollet (Democrat), and Chris Kilduff (Democrat).
What is the current status of HB 2428?
This bill died with 2019-2020 Regular Session. It reached “Passed House” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HB 2428?
Track HB 2428 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 2428

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of HB 2428

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →